Compare GSK plc (GSK) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Ulta Beauty Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Ulta Beauty Inc trades at $570.37 (market cap $24.12B). The key difference: GSK plc is far larger — about 3.8× Ulta Beauty Inc's market cap, and GSK plc pays a 3.9% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Ulta Beauty Inc for 92 Days on average.
| GSK | ULTA | |
|---|---|---|
Market Cap | $91.88B | $24.12B |
Volume | 7,730,529 | 457,598 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $706.82 |
52-Week Low | $43.24 | $450.75 |
Typical Hold Time | 93 Days | 92 Days |
Enterprise Value | $111.88B | $26.43B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
ULTA trades at $564.21, up 3.43% today, with a bullish technical outlook and strong institutional support. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 guidance, driven by e-commerce momentum. Valuation metrics show a P/E of 20.55 and P/S of 1.92, while profitability remains robust with a 9.34% net income margin and 46.12% ROE.
The stock offers growth potential with a consensus price target of $624.93, but faces risks from margin pressure and flat store traffic. Execution on raised guidance and expansion into wellness categories are key catalysts, though consumer spending volatility and promotional intensity could limit upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
